Compare Amgen, Inc. (AMGN) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Zoom Video Communications, Inc. — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Zoom Video Communications, Inc. trades at $90.12 (market cap $26.32B). The key difference: Amgen, Inc. is far larger — about 7.5× Zoom Video Communications, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | ZM | |
|---|---|---|
Market Cap | $196.12B | $26.32B |
Sector | Health | Technology |
52-Week High | $388.16 | $111.88 |
52-Week Low | $271.18 | $69.77 |
Enterprise Value | $241.41B | $18.66B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Zoom Communications (ZM) trades at $89.76, showing modest daily movement with a slight 0.13% decline. The stock maintains bullish technical signals with strong moving average support and trades near pivot point resistance at $91. Fundamentally, Zoom demonstrates robust profitability with 77.4% gross margins and 42% net income margins, while recent Q1 2026 earnings beat expectations. The company continues expanding AI capabilities through acquisitions like Common Room and new Virtual Agent offerings.
Zoom presents a compelling value opportunity trading below analyst consensus targets with 32% upside potential. Strong cash generation, AI integration progress, and strategic Anthropic investment provide catalysts, though competitive pressures from Microsoft and Google remain key risks. Wall Street maintains cautious optimism with mixed analyst ratings reflecting growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
